2026 Mass Tort Litigation Update: Talc, Depo-Provera, and Cartiva — What Your Case Means Right Now
You are reading this at 2 a.m. because someone you love — or you yourself — used a product you trusted, and your body broke in a way no one warned you about. Maybe it was years of talcum powder and a cancer diagnosis that came out of nowhere. Maybe it was the contraceptive injection you got every three months, and now there is a tumor pressing against your brain. Maybe it was a toe implant that was supposed to end the pain and instead made it worse. You found a headline about mass tort litigation, and now you are trying to figure out whether there is a case, where it stands, and whether you are already too late.
We are Attorney911 — The Manginello Law Firm, PLLC. We are a trial firm that takes catastrophic-injury and wrongful-death cases, and we are writing this page as the senior trial attorneys who build these cases, not as a marketing office recycling a news wire. Everything below is what we would tell you if you were sitting across our desk in Houston, Austin, or Beaumont — or if we were on the phone with you at 2 a.m., which is when our live staff answers, not an answering service. The call is free. We do not get paid unless we win your case.
Three mass torts are moving through the American court system right now at three very different stages of maturity — talc, Depo-Provera, and Cartiva — and the stage your case is in changes everything about strategy, timing, and what you need to do today. Here is what each one is, where it stands, and what it means for you.
Three Mass Torts at Three Different Stages — Where Your Case Fits
Mass tort litigation is not like a single car-crash lawsuit. When thousands of people are injured by the same product, the federal court system often consolidates the pretrial work — discovery, expert challenges, bellwether test trials — into one courtroom through a mechanism called multidistrict litigation, or MDL. Each plaintiff keeps their own individual case with their own specific injuries, but the shared questions — did the product cause cancer, did the manufacturer know, did it warn anyone — get answered once, together, before cases are sent back to their home courts for individual trial or settlement.
The three mass torts in this update sit at three different points on that timeline, and knowing which one is yours tells you what is coming:
Talc is in its late stage. Tens of thousands of plaintiffs have filed claims alleging that prolonged use of talcum powder products caused ovarian cancer or mesothelioma. The defendant corporation attempted to resolve the litigation through bankruptcy three separate times — each attempt was dismissed by the courts. The cases are back in the traditional tort system, and the prevailing view in 2026 is that a global settlement framework may finally be achievable. What this means for you: if you have a talc case, the machinery of resolution is already turning, but your individual case strength — your exposure history, your pathology, your diagnosis — still determines which settlement tier you land in or whether you should hold out for individual trial.
Depo-Provera is in its middle phase. Plaintiffs allege that prolonged use of the injectable contraceptive caused meningioma brain tumors, and that the manufacturer failed to adequately warn about that risk. Coordinated proceedings are advancing, and bellwether trials — the test cases a court sends to trial first to see how juries respond to the evidence — are being developed. What this means for you: your case is being built right now alongside thousands of others, and the bellwether outcomes will shape settlement value, but specific causation proof — tying your tumor to your Depo-Provera use — is the work that has to happen on your case individually, regardless of what the bellwethers produce.
Cartiva is in its earliest stage. The synthetic cartilage implant, designed to treat arthritis pain in the big toe joint, is the subject of growing legal scrutiny following reports of device failure, persistent pain, and revision surgeries. Courts are still establishing the procedural framework, and the scientific evidence on the implant’s failure mechanisms is still being assembled. What this means for you: this is the stage where evidence preservation is most urgent and most often missed — the explanted device from your revision surgery is the single most important piece of physical evidence, and it may already be gone.
If you or a family member has been affected by any of these products, the single most important step is to talk to a lawyer now — not next month, not after the next doctor’s appointment, but now, because the evidence that decides these cases is on a clock that has already started running.
Talc Litigation: The Late-Stage Giant Approaching Resolution
The talc litigation against Johnson & Johnson is one of the longest-running and most closely watched product liability battles in the history of American civil courts. Tens of thousands of plaintiffs have alleged that prolonged use of talcum powder products — some applying the powder for daily perineal hygiene over decades — resulted in ovarian cancer or mesothelioma. The core theory is that the talc was contaminated with asbestos during mining and manufacturing, and that Johnson & Johnson knew about the cancer risk for decades and concealed it from consumers.
The Bankruptcy Strategy That Failed Three Times
Johnson & Johnson attempted to resolve the talc litigation through a corporate restructuring maneuver widely known as the “Texas two-step” — creating a separate subsidiary entity to hold the talc liability, then filing that subsidiary into bankruptcy to force a global settlement outside the tort system. The third and most recent attempt, filed through an entity called Red River Talc LLC, was dismissed by the U.S. Bankruptcy Court for the Southern District of Texas on March 31, 2025. The court found vote-solicitation irregularities and impermissible nonconsensual third-party releases. Three bankruptcy attempts, three dismissals. The cases are back in the traditional court system where they belong — in front of juries.
What this means practically: there is no bankruptcy proceeding standing between you and your right to have your case heard. The path to resolution runs through the tort system — either through a negotiated global settlement framework or through individual trials in your home venue.
Where the Talc MDL Stands
The federal multidistrict litigation — MDL No. 2738, consolidated in the District of New Jersey before Judge Michael A. Shipp — reported 68,029 actions pending as of June 2026. That number alone tells you the scale: this is not a few hundred unhappy customers, it is a body of litigation so large that the federal court system created a dedicated courtroom to manage it.
The Verdict Record That Drives Settlement Value
Juries have already spoken on talc, and the numbers they returned are what drive the settlement pressure today. In 2018, a Missouri jury returned a $4.69 billion verdict against Johnson & Johnson in a case involving 22 women who alleged talc caused their ovarian cancer. That verdict was reduced on appeal to approximately $2.12 billion by the Missouri Court of Appeals in June 2020, and the United States Supreme Court declined to review the case in June 2021 — meaning the reduced award stands as a final, affirmed judgment. That is not a press release number. That is a dollar figure the highest court in the country let stand.
The jury’s original $4.69 billion award was reduced to approximately $2.12 billion on appeal, and the U.S. Supreme Court denied certiorari on June 1, 2021 — making the reduced figure a final, affirmed judgment.
That affirmed verdict is the floor that settlement negotiations start from, and it is why the prevailing industry view is that 2026 may bring a meaningful global resolution. Johnson & Johnson’s financial position has strengthened considerably since the litigation-driven lows — the company’s stock price has nearly doubled — giving it both the financial capacity and the strategic incentive to put the talc litigation behind it.
What Determines Your Individual Talc Case Value
A global settlement framework, when achieved, typically tiers payouts by injury severity, exposure duration, and diagnostic category. Where you land in that tier structure depends on factors specific to your case:
- Diagnosis type: Mesothelioma cases carry the highest individual valuations because the disease is aggressive, terminal, and has a signature relationship with asbestos exposure. Ovarian cancer cases are valued based on stage at diagnosis, treatment history, and survival status. Wrongful death claims involve lost income, loss of consortium, and funeral expenses.
- Exposure proof: How long you used the product, which specific products, how frequently, and whether you can produce purchase records, witness testimony, or household history. The strongest cases have decades of documented daily use.
- Pathological evidence: For talc cases, pathological analysis can detect talc particles and asbestos bodies in ovarian or lung tissue. Tissue blocks and slides are retained per hospital pathology protocols but may be discarded after 10 to 25 years depending on institutional policy. Obtaining and preserving these specimens before disposal can be the difference between a top-tier case and one that cannot prove specific causation.
- Diagnostic timeline: When you were diagnosed, when you connected the diagnosis to talc exposure, and whether your state’s statute of limitations has run — or whether the discovery rule extends your deadline.
If your loved one died from ovarian cancer or mesothelioma and you believe talc exposure was the cause, the wrongful death claims process involves specific procedural steps — appointment of a personal representative, survival action versus wrongful-death claim splits, and beneficiary class determination — that vary by the decedent’s state of residence.
Depo-Provera Litigation: Bellwether Trials and the Meningioma Connection
Depo-Provera — the brand name for depot medroxyprogesterone acetate, an injectable contraceptive administered every three months — is the subject of a mass tort in its middle phase. Plaintiffs allege that prolonged use of the injection caused the development of meningioma brain tumors, and that the pharmaceutical manufacturer failed to adequately warn patients and prescribing physicians about that risk.
The Medical Connection: Progestin and Meningioma Growth
Meningiomas are tumors that arise from the meninges — the membranes that surround the brain and spinal cord. They are typically slow-growing and often benign, but their location can cause devastating neurological symptoms depending on what structures they compress. Meningiomas are known to express progesterone receptors, which means they can respond to hormonal signals. The theory in this litigation is that prolonged exposure to the synthetic progestin in Depo-Provera stimulated the growth of these tumors in women who used the injection for years.
The injuries in these cases can be catastrophic. Depending on tumor location and size, patients may require neurosurgical resection — brain surgery — and may suffer permanent cognitive, visual, or motor deficits. Even when the tumor is successfully removed, ongoing neurological monitoring is required because meningiomas can recur. The lifetime cost of a serious brain injury — surgery, rehabilitation, monitoring, lost earning capacity, and the human toll of living with the aftermath — is why these cases occupy a mid-to-high value tier in the mass tort landscape.
If you or a loved one developed a meningioma after prolonged Depo-Provera use, the brain injury litigation process involves specific proof requirements that differ from other injury cases — neuropsychological testing, advanced imaging, and expert testimony on specific causation.
What Bellwether Trials Mean for Your Case
Bellwether trials are test cases selected from the MDL to go to trial first. Their purpose is not to resolve every case but to produce verdicts that tell both sides what a jury thinks of the evidence. When a bellwether produces a large plaintiff verdict, settlement pressure builds. When it produces a defense verdict, the plaintiffs’ leverage weakens. Either way, the bellwether outcomes shape the settlement framework that eventually applies to your individual case.
What you need to understand: your case is not the bellwether. Your case has its own specific facts — your own Depo-Provera usage history, your own tumor pathology, your own surgical outcome, your own neurological deficits. The bellwether tells the parties what the average case is worth. Your individual proof tells them what your case is worth. A woman who used Depo-Provera for 15 years, developed a large parasagittal meningioma requiring craniotomy, and suffered permanent visual field loss has a different case from a woman who used it for 3 years, had a small convexity meningioma removed with full recovery, and returned to work.
The Disclosure Issue: Third-Party Litigation Funding Under Judicial Scrutiny
A development unique to the Depo-Provera litigation is the presiding judge’s signaled interest in disclosure of third-party litigation funding agreements. The court has indicated that funding contracts may be subject to scrutiny as part of discovery proceedings. This means that if you have entered into a pre-settlement funding agreement — a cash advance against your anticipated settlement — that contract could become part of the litigation record.
This is not necessarily a bad thing for you, but it is something you need to understand. Non-recourse litigation funding — where repayment is only owed if you win — is a legitimate tool for plaintiffs who need to pay medical bills and living expenses while their case moves through years of litigation. But the terms of those agreements vary widely, and some carry effective interest rates that consume a significant portion of your recovery. Before signing any funding agreement, you should have it reviewed by your attorney. The litigation funding industry is not regulated the way consumer lending is, and the contract you sign at your kitchen table at 2 a.m. may not be the deal it appears to be.
Cartiva Toe Implant: The Emerging Medical Device Docket
Cartiva — a synthetic cartilage implant made from polyvinyl alcohol hydrogel — was designed to treat arthritis pain in the big toe joint (hallux rigidus) as an alternative to joint fusion surgery. The implant was promoted as preserving motion and avoiding the recovery burden of traditional fusion. Plaintiffs now allege that the device fails through fragmentation, wear, loosening, and material degradation — causing persistent pain, reduced mobility, and the need for revision surgery to remove the failed implant and fuse the joint anyway.
This litigation is in its earliest stage, and that fact creates both risk and opportunity for you.
The Preemption Question That Could Decide Your Case
Medical device litigation in the United States runs through a federal preemption analysis that can end your case before it begins — or leave the courthouse door wide open. The analysis depends on which FDA regulatory pathway the device traveled to market:
“The 510(k) review standard is comparative, whereas the PMA standard relies on an independent demonstration of safety and effectiveness.”
That distinction — from the FDA’s own published guidance — is the line that decides whether you can sue the manufacturer for a defective device design.
If a device entered the market through the 510(k) “substantial equivalence” pathway — where the manufacturer only had to show the device was similar to something already on the market — federal law does not bar state-law design-defect and failure-to-warn claims. The manufacturer can be held accountable for building a dangerous device, even though the FDA waved it through.
If a device entered the market through Premarket Approval (PMA) — the FDA’s most rigorous review, requiring clinical trials and independent safety demonstration — federal law can preempt state-law design-defect claims. In that scenario, the path forward is a “parallel claim” — proving the manufacturer violated a specific FDA regulation it had promised to follow, and that the violation caused the device to fail in your body.
The specific regulatory pathway for any given device must be confirmed against the FDA’s device-registry database at the time your case is built. This is one of the first questions a product liability attorney asks when evaluating a medical device case — because it determines the entire legal theory. Our practice areas include the full range of product liability and medical device cases, and this analysis is where the work begins.
The Evidence You Cannot Afford to Lose
For Cartiva cases, the single most critical piece of evidence is the explanted device itself — the physical implant removed during your revision surgery. That device is the physical proof of how and why it failed: fragmentation patterns, wear surfaces, material degradation, loosening at the bone interface. When an explanted device is analyzed by a qualified biomedical engineer, the failure mode tells the story of whether the device was defectively designed, defectively manufactured, or both.
Here is the problem: explanted devices are routinely discarded as medical waste unless someone specifically instructs the surgeon to preserve them. Once the device goes into the biohazard bin, it is gone forever. No amount of legal process can recover a physical object that was incinerated after surgery.
If you have not yet had your revision surgery: tell your surgeon, in writing, before the operation, that the explanted device must be preserved and sent to your attorney. Coordinate with your lawyer’s office before the surgery date.
If you have already had your revision surgery: contact your surgeon’s office immediately and ask whether the explant was preserved. Some hospitals retain explanted hardware for a period. Most do not, unless asked. Every day you wait is a day closer to the answer being “no.”
For guidance on how surgical implant injury cases work — including the evidence chain that makes or breaks them — our surgical implant injury guide walks through the proof requirements that apply across device cases, from mesh to joints to synthetic cartilage.
The Law That Governs Your Claim — Product Liability, FDA Regulation, and Preemption
Product liability law in the United States rests on several pillars, and which ones apply to your case depends on the product, the injury, and the pathway the product took to market.
Failure to Warn — The Central Theory in All Three Mass Torts
Every one of these three mass torts shares a common legal theory at its core: the manufacturer failed to warn consumers and their doctors about a known or reasonably knowable risk.
For talc products, the allegation is that Johnson & Johnson knew for decades that its talcum powder could be contaminated with asbestos and could cause ovarian cancer and mesothelioma, and concealed that knowledge from consumers and regulators. The theory is not just failure to warn — it is fraudulent concealment. When a jury hears that a company’s own internal testing detected asbestos in its talc years before it stopped selling the product, and that it never told a single consumer, that evidence drives both compensatory and punitive damages.
For Depo-Provera, the allegation is that the pharmaceutical manufacturer did not adequately disclose the meningioma risk on the drug’s label or in its communications to prescribing physicians. Under the legal doctrine applicable to brand-name prescription drugs — established by the United States Supreme Court in Wyeth v. Levine — a brand-name drug manufacturer is not shielded from state-law failure-to-warn claims merely because the FDA approved the drug’s label. The manufacturer had the ability to strengthen its warning unilaterally through the FDA’s Changes Being Effected process, and if it knew or should have known about the meningioma risk and failed to act, it can be held accountable.
For Cartiva, the allegation is that the device manufacturer failed to warn surgeons and patients about the rates of device failure, fragmentation, and revision surgery. The specific legal path depends on the FDA regulatory pathway, but the warning theory is universal — a company that sells a device implanted in the human body has a duty to tell the surgeon and the patient what can go wrong.
Strict Products Liability — Design Defect and Manufacturing Defect
Beyond failure to warn, these cases can pursue strict liability theories:
Design defect: The product was unreasonably dangerous as designed — there was a safer alternative design the manufacturer could have used. For talc, this theory applies if the product design incorporated asbestos-contaminated talc when asbestos-free sources or cornstarch alternatives were available. For Cartiva, this theory applies if the synthetic cartilage material or the implant geometry was inherently prone to failure in the big toe joint’s mechanical environment.
Manufacturing defect: The product departed from its intended design — a specific lot or production run was contaminated, degraded, or otherwise defective. For talc, this theory applies where plaintiffs can prove that specific batches of talcum powder were contaminated with asbestos fibers during mining or processing. For Cartiva, this theory may apply if specific lots or production runs show elevated failure rates traceable to a manufacturing variance.
Negligence and Fraudulent Concealment
All three litigations also pursue negligence claims — that the manufacturers failed to exercise reasonable care in testing, safety evaluation, post-market surveillance, and consumer disclosure. And where the evidence shows that a manufacturer knew of a risk and deliberately concealed it — as talc plaintiffs have alleged Johnson & Johnson did for decades — the fraudulent concealment theory opens the door to punitive damages.
The Discovery Rule and Your Statute of Limitations
Statutes of limitations for product liability and personal injury claims vary by state — most fall between two and three years, though some states allow longer. The critical doctrine for mass torts involving latent injuries — cancer that appears decades after exposure, a brain tumor that grows silently for years — is the discovery rule:
The clock to file your lawsuit generally does not start ticking on the day you were exposed to the product. It starts when you discovered, or by reasonable diligence should have discovered, both your injury and its connection to the product. For a woman diagnosed with ovarian cancer in 2024 who used talcum powder from 1980 to 2005 and only learned in 2025 that talc may have caused her cancer, the statute of limitations may have started running in 2025 — not 1980, not 2005, not even 2024.
This is why people who assume they are “too late” are often wrong. But this doctrine has limits. Some states impose a statute of repose — an absolute outer deadline that can cut off a claim even before discovery. The specific deadline for your state, your injury type, and your circumstances must be confirmed by an attorney licensed in your jurisdiction. What we can tell you is this: do not assume you are out of time. Call and ask.
The Defendant’s Structure — Who You Are Really Up Against
In mass tort litigation, the company on the product label is rarely the only entity responsible — and identifying the full defendant stack is where corporate structure analysis becomes case value.
Johnson & Johnson — The Corporate Structure
Johnson & Johnson is a global pharmaceutical and consumer products conglomerate. The talc liability has been shuffled through a chain of entities — Johnson & Johnson Consumer Inc. (the historical talc seller), LTL Management LLC and Red River Talc LLC (entities created through divisional mergers to hold talc liability for the bankruptcy strategy), and Kenvue Inc. (the consumer-health spinoff that now owns brands like Band-Aid and Tylenol, with indemnity arrangements back to J&J). When you sue “Johnson & Johnson” for talc, you are navigating a corporate web deliberately constructed to compartmentalize liability. The operating entity, the liability-holding entity, and the public parent are different companies with different balance sheets — and naming the right ones in your complaint is foundational work.
The coverage-tower reality for a corporation of J&J’s scale is substantial. J&J is not a company that carries a single $750,000 insurance policy — it is a balance-sheet defendant with self-insured retention, layered excess coverage, and the financial capacity to resolve tens of thousands of claims. But that also means it has the resources to fight every case it chooses to fight, and it will choose to fight cases it believes are weak. The strength of your individual proof — your exposure history, your pathology, your diagnosis — is what moves you from the defense column to the settlement column.
The Depo-Provera and Cartiva Manufacturers
The injectable contraceptive at the center of the Depo-Provera litigation is a brand-name pharmaceutical product. Under Wyeth v. Levine, the brand-name manufacturer is the proper defendant for failure-to-warn claims — it had the power to change the label and is accountable for not doing so. If your pharmacy filled your prescription with a generic version, the legal analysis shifts: under PLIVA v. Mensing, generic manufacturers cannot unilaterally change their labels (they must match the brand’s), which creates a preemption barrier. Identifying whether you received the brand-name or generic version — from your pharmacy fill records — is one of the first intake questions.
The Cartiva synthetic cartilage implant was developed and commercialized by corporate entities identifiable through the FDA’s device-registry records. As with all medical device cases, the manufacturer, the distributor, and any contract manufacturers are all potential defendants, and the corporate structure must be traced from the product’s nameplate and FDA filings before naming entities in a complaint.
The Evidence Clock — What Records Exist and How Fast They Disappear
Every mass tort case is a race against evidence destruction. Some of that destruction is deliberate — a company shredding documents it was required to keep. Most of it is not — it is the routine, legal, scheduled purging of records that happens when no one has demanded they be preserved. Here is what exists, who holds it, and how fast it can legally die.
Medical and Pharmacy Records
Your complete medical records establish your product usage history, your diagnosis timeline, and the causal connection between exposure and injury. They are the foundation of specific causation in every mass tort. Medical records are generally retained per state record-keeping statutes, but pharmacy records and historical prescription data can be purged after 7 to 10 years depending on the provider. For Depo-Provera cases, the injection schedule — when you received each shot, at what dose, for how many years — lives in your medical and pharmacy records. For talc cases, your medical history establishes when the cancer was diagnosed and when you first connected it to talc use. Request these records now, before routine purging thins them.
Pathology Specimens and Tumor Tissue
For talc cases, pathological analysis can detect talc fibers and asbestos bodies in ovarian or lung tissue. For Depo-Provera cases, meningioma tumor pathology and hormonal receptor analysis can support the specific-causation link between the progestin exposure and tumor growth. Tissue blocks and slides are retained per hospital pathology protocols, but institutional policies vary — some retain specimens for 10 years, some for 25 years, and some smaller facilities purge sooner. If your loved one has died and an autopsy was performed, or if tumor tissue was removed during surgery, finding out whether the pathology blocks still exist is urgent. Once they are discarded, they cannot be recreated.
Explanted Cartiva Devices
As discussed above, the physical Cartiva implant removed during revision surgery is the single most important piece of evidence in a Cartiva case. Explanted devices are routinely discarded as medical waste unless specifically preserved at the time of revision surgery. Immediate coordination with the revision surgeon is essential — before the device is lost. The surgical operative report from the revision procedure documents the failure mechanism the surgeon observed: fragmentation, wear, loosening, material degradation. That report is durable — it lives in your medical record. The device itself is not, unless someone saved it.
Internal Corporate Documents
The most powerful evidence in any mass tort is often the manufacturer’s own internal records — safety testing data, adverse event reports, regulatory correspondence, internal communications about known risks, and the timeline of what the company knew versus when it modified its warnings. These documents are discovery targets, obtained through the litigation process, and they drive punitive damages where they show corporate knowledge of risk coupled with deliberate concealment. Document retention policies, litigation holds, and corporate reorganizations all create ongoing risk of loss — which is why the coordinated MDL discovery process exists to force these documents into the record before they disappear.
Historical Product Packaging, Labeling, and Marketing Materials
What warnings and representations were provided to consumers at the time you used the product? For talc cases, this includes the historical labeling and marketing of talcum powder products over the decades of your exposure. For Depo-Provera, this includes the drug’s label at the time you received your injections — did it warn about meningioma risk? For Cartiva, this includes the surgeon-facing marketing materials and patient consent forms. Consumer product packaging is rarely retained by users over the years of latency typical in these mass torts. Archival collections and regulatory filing repositories may be the best available sources — and your attorney’s office can help locate them.
What Your Case Is Worth — Honest Valuation Across Three Mass Torts
Individual case values across these three mass torts span an extreme range — from approximately $250,000 on the low end to $25,000,000 or more on the high end. We are not going to tell you what your case is worth, because we have not seen your records. What we will tell you is how the valuation works and what drives it.
Talc Cases
Talc mesothelioma and late-stage ovarian cancer wrongful death cases with strong exposure proof and punitive damage support represent the highest tier. The affirmed $2.12 billion verdict in Ingham v. Johnson & Johnson — reduced from $4.69 billion but let stand by the Supreme Court — sets the ceiling for what juries are willing to award in talc cases, though that was a consolidated case of 22 plaintiffs. Individual mesothelioma verdicts in the talc context have reached eight figures. Ovarian cancer cases are valued based on stage, treatment history, survival status, and the strength of the exposure-and-pathology proof.
Depo-Provera Cases
Meningioma cases with surgical resection and documented neurological deficits occupy a mid-to-high tier, pending bellwether trial outcomes. The value driver is specific causation — can you prove that your meningioma was related to your Depo-Provera use rather than being one of the meningiomas that occur in the general population? Women with long Depo-Provera use histories (10+ years), large or multiple tumors, significant surgical complications, and permanent neurological deficits will occupy the highest tier. Women with shorter use histories, small tumors removed without complication, and full recovery will occupy a lower tier.
Cartiva Cases
Revision surgery cases with chronic pain and mobility loss represent the lower tier of the three mass torts, with individual values dependent on the degree of permanent functional impairment and the strength of device-specific defect proof. A patient who required multiple revision surgeries, developed chronic regional pain syndrome, and has permanent gait abnormality will have a higher-value case than a patient who had one revision surgery with return to near-normal function.
How a Real Number Is Built
A real damages number is not plucked from a verdict report. It is built from:
- A life-care plan — a formal medical-economic document, built to a national professional standard, that lays out every surgery, therapy, medication, and caregiver hour you will need for the rest of your life, priced at current market rates.
- A forensic economist’s present-value calculation — because a jury pays the entire future in one check today, and that check must account for the interest the money will earn over your remaining life expectancy.
- Lost earning capacity — not just the wages you have already lost, but the lifetime of earnings and benefits you will never receive because of what the product did to your body. Fringe benefits — health insurance, retirement contributions, paid leave — run close to 30% of total compensation for a typical private-sector worker, and a complete claim counts all of it.
- Pain, suffering, and loss of quality of life — the human losses no receipt can measure, and in some states, the lost value of life itself.
- Punitive damages — where the evidence shows the manufacturer knew of the risk and chose to conceal it, a jury can award damages designed to punish, not just compensate. The talc litigation’s fraudulent-concealment evidence is the engine behind its largest verdicts.
Past results depend on the facts of each case and do not guarantee future outcomes. What we can tell you is that the adjuster’s first offer is always a fraction of the true number — because the adjuster’s job is to close the file for the least money possible, not to make you whole. Knowing the real cost of your care, built by a life-care planner and reduced to present value by a forensic economist, is how you refuse that first offer with confidence.
The Defense Playbook — What the Other Side Will Do and How We Counter
Lupe Peña spent years inside a national insurance-defense firm before he came to our side of the table. He sat in the rooms where adjusters and their software decided how to deny, delay, and devalue claims. He knows how the machine works because he used to run it. Here is what the defense does in mass tort cases — and where each play breaks down.
Play 1: “The FDA Approved It, So You Cannot Sue Us”
This is the preemption defense, and it is the manufacturer’s first and strongest move. The counter depends on the product type and the regulatory pathway. For brand-name drugs like Depo-Provera, the Supreme Court held in Wyeth v. Levine that FDA approval does not preempt state-law failure-to-warn claims — the manufacturer could have strengthened its warning and chose not to. For 510(k)-cleared medical devices, the Supreme Court held in Medtronic v. Lohr that the 510(k) pathway does not impose device-specific federal requirements that trigger preemption. For PMA-approved devices, the path is narrower — a “parallel claim” proving the manufacturer violated a specific FDA regulation — but it is not closed. The preemption analysis is product-specific and pathway-specific, and it is one of the first things a product liability attorney evaluates.
Play 2: “Your Cancer Was Caused by Something Else”
The defense will argue that your ovarian cancer was caused by genetics, BRCA mutations, hormone therapy, or other environmental factors — not talc. Your meningioma was a naturally occurring tumor that women develop at baseline rates — not Depo-Provera. Your toe pain was caused by your own anatomy, your activity level, or your weight — not the Cartiva implant.
The counter is specific causation proof: documented exposure history (how long, how much, which product), pathological evidence (talc fibers in tissue, tumor hormonal receptor analysis), the dose-response relationship in the scientific literature, and expert testimony from qualified oncologists, neurologists, and biomedical engineers. The defense’s alternative-cause argument is only as strong as the evidence it can produce for that alternative. When your exposure history is long and well-documented and the defense cannot point to a specific alternative cause in your medical record, the “something else” argument weakens.
Play 3: “You Waited Too Long to Sue”
The defense will argue that the statute of limitations has expired. The counter is the discovery rule — for latent injuries, the clock starts when you discovered or should have discovered the injury and its connection to the product. For many mass tort plaintiffs, that connection was made only recently — when they saw a news report, heard from a family member, or were told by a doctor that their condition might be related to a product they used years ago. The specific deadline for your state and circumstances must be confirmed by an attorney, but do not let the defense’s statute-of-limitations argument keep you from calling. You may have more time than you think.
Play 4: “We Already Warned About That”
The defense will point to the product’s label and argue that it contained adequate warnings. The counter is two-fold: first, was the warning adequate in content — did it actually describe the risk in terms a patient or prescribing physician would understand and act on? Second, was the warning timely — did it exist at the time you used the product, or was it added years later after you were already injured? For Depo-Provera, the question is whether the meningioma warning was on the label during the years you received your injections. For Cartiva, the question is whether the surgeon-facing materials disclosed the revision-surgery rates and failure modes at the time your implant was placed. Labeling history is discoverable and is often the backbone of a failure-to-warn case.
Play 5: The Quick Settlement Offer
In late-stage mass torts like talc, where global settlement frameworks are being discussed, you may receive communications about settlement offers. Some of these are legitimate. Some are designed to close your case for a fraction of its value before you have an attorney who can evaluate it. Never sign a release, accept a check, or agree to a settlement without having an attorney review the terms. A release is final — once you sign it, you cannot reopen your case, no matter what happens to your health.
Your First Steps — What to Do Right Now to Protect Your Claim
Step 1: Gather Your Medical and Product History
Write down everything you can remember about your use of the product:
– Talc: Which brands did you use? How often — daily, weekly? For how many years? How did you use it — perineal hygiene, body powder, other? Who else in your household used it? Can you find any old purchase records, receipts, or containers?
– Depo-Provera: When did you start receiving injections? How often — every 3 months? For how many years total? Which doctor or clinic administered them? Do you have your medical records from that period? When were you diagnosed with a meningioma?
– Cartiva: When was your implant surgery? Who was the surgeon? At which hospital? When did the pain start or worsen? Have you had revision surgery? If so, when, and by whom? Do you have your operative reports?
Step 2: Request Your Records
Contact every doctor, clinic, pharmacy, and hospital that treated you or prescribed the product. Request your complete medical records, pharmacy fill history, and surgical operative reports. Do this in writing. Keep copies of your requests. Medical records are yours — federal law gives you the right to access them — but the retention clock is ticking.
Step 3: Preserve Physical Evidence
If you are facing revision surgery for a Cartiva implant, tell your surgeon — in writing, before the operation — that the explanted device must be preserved and sent to your attorney. If a loved one has died and an autopsy was performed, or if tumor tissue was removed during surgery, contact the pathology department and ask whether tissue blocks and slides still exist.
Step 4: Do Not Sign Anything
Do not sign a release, a settlement agreement, a pre-settlement funding contract, or any other legal document without having an attorney review it. Do not give a recorded statement to an insurance adjuster or a “claims representative” who calls you. Do not post about your case on social media. Do not discuss your potential claim with anyone other than your attorney and your immediate family.
Step 5: Call a Lawyer
The preservation letter — the document that orders the manufacturer, the hospital, and every other evidence custodian to freeze the records before they are destroyed — goes out the day you call. Not the day you sign a retainer. Not the day you have your first full consultation. The day you pick up the phone. That is why our line is answered 24 hours a day, 7 days a week, by live staff — not a machine.
Call 1-888-ATTY-911. The consultation is free. We do not get paid unless we win your case.
The Medicine — What Happened to Your Body and How We Prove It
Talc and Cancer: The Mechanism
Talc is a mineral mined from the earth, often from deposits located near asbestos ore. When talc is mined from these deposits, it can be contaminated with asbestos fibers — durable, microscopic needles that the human body cannot break down or clear. When talcum powder is applied to the perineal area, talc particles — and any asbestos fibers mixed in — can travel through the vagina, uterus, and fallopian tubes to the ovaries, where they lodge in tissue and cause chronic inflammation. Over decades, that inflammation can drive malignant transformation — ovarian cancer. When talcum powder is inhaled, asbestos fibers can lodge in the pleura — the lining of the lungs — and cause mesothelioma, a cancer essentially specific to asbestos exposure.
The latency is the cruelest part. A woman who used talcum powder in her twenties may not develop ovarian cancer until her sixties. By then, the connection to a product she stopped using decades ago is not obvious — which is exactly why the discovery rule exists and why the manufacturer’s concealment of internal testing data is so devastating.
For a toxic tort claim involving talc or asbestos exposure, the proof is built from exposure history, pathological analysis of tumor tissue, and the scientific literature on the talc-cancer causal link — including any internal corporate documents obtained through discovery that show what the manufacturer knew and when.
Depo-Provera and Meningioma: The Mechanism
Depo-Provera delivers a high dose of medroxyprogesterone acetate — a synthetic progestin — that suppresses ovulation for three months per injection. Meningiomas are tumors of the meninges, the membranes surrounding the brain and spinal cord. A significant percentage of meningiomas express progesterone receptors, meaning the tumor cells have molecular docking sites that respond to progesterone and related compounds. The theory in this litigation is that years of repeated, high-dose progestin exposure from Depo-Provera injections stimulated the growth of these tumors — causing them to grow larger, faster, or to appear in women who otherwise would never have developed a symptomatic meningioma.
The symptoms depend on where the tumor sits. A meningioma pressing on the optic nerve causes vision loss. One pressing on the motor cortex causes weakness or seizures. One near the frontal lobe causes personality changes and cognitive decline. The diagnosis comes from MRI — meningiomas have a characteristic appearance as extra-axial, dural-based enhancing masses. The treatment ranges from watchful waiting for small, asymptomatic tumors to neurosurgical resection for large or symptomatic ones. The surgery itself carries risks — infection, bleeding, stroke, neurological deficit — and the recovery can be long and incomplete.
The proof problem: meningiomas are the most common primary brain tumor, and they occur more frequently in women than men — which the defense will use to argue your tumor was naturally occurring, not drug-induced. The counter is dose and duration: a woman who used Depo-Provera for 15 years and developed a large, progesterone-receptor-positive meningioma has a stronger specific-causation case than a woman who used it for 2 years and developed a small tumor. Tumor pathology — the receptor analysis — is part of the proof.
Cartiva and Device Failure: The Mechanism
The Cartiva implant is a small cylinder of polyvinyl alcohol hydrogel — a water-containing polymer — inserted into the big toe joint to replace damaged cartilage and preserve motion. The theory of the case is that the material degrades inside the joint over time: it fragments, it wears, it loosens from the bone interface, and instead of cushioning the joint it becomes a source of chronic pain and inflammation. The patient who had the implant to avoid fusion surgery ends up needing fusion surgery anyway — but now after months or years of suffering and an additional operation.
The diagnosis of device failure comes from imaging (X-rays showing implant position and bone changes, MRI showing soft-tissue reaction), clinical exam (persistent pain, reduced range of motion, gait abnormality), and ultimately the surgical findings at revision — what the surgeon sees when they open the joint and remove the device. Fragmentation, wear debris, synovitis, and bone resorption around the implant are the physical signatures of failure.
The proof problem: the defense will argue the failure was caused by patient factors — activity level, weight, surgical technique, or the underlying arthritis progression. The counter is the pattern: if multiple patients with the same implant experience the same failure mode at similar time intervals, that pattern points to the device, not the patient. The explanted device itself, if preserved and analyzed by a biomedical engineer, can show whether the failure was a material property issue (design defect) or a specific-production-run issue (manufacturing defect).
Frequently Asked Questions
How long do I have to file a mass tort claim?
The statute of limitations varies by your state of residence — most states allow two to three years for personal injury and product liability claims, though some allow longer. For mass torts involving latent injuries like cancer or brain tumors, the discovery rule may extend your deadline: the clock generally starts when you discovered, or should have discovered, both your injury and its connection to the product. Some states also have a statute of repose — an absolute outer deadline that can bar a claim regardless of discovery. You must have an attorney confirm the specific deadline for your state and circumstances, but do not assume you are out of time until someone has checked.
Do I still have a case if I used the product years ago?
Yes, potentially. The discovery rule exists precisely for situations like this — where the injury does not appear until years or decades after the exposure. If you were exposed to talc in the 1980s and diagnosed with ovarian cancer in 2024, and you only learned in 2025 that talc may have caused your cancer, your filing deadline may have started in 2025. The key is when you knew or should have known about the connection. Call us and we will help you figure out whether your window is still open.
What if I already settled with the company — can I still sue?
If you signed a release or settlement agreement with the manufacturer, your claim against that manufacturer is likely closed — releases are final. However, if you signed something you did not understand, or if you were pressured into signing, or if the release was obtained through fraud, there may be grounds to challenge it. Do not assume the release is ironclad until an attorney has reviewed it. And if you have not signed anything, do not sign anything now — especially not a “quick settlement” check that arrives in the mail with a release printed on the back.
I had a Cartiva implant and I am in pain but have not had revision surgery yet — what should I do?
Call us before your revision surgery. The single most important evidence in a Cartiva case is the explanted device — the physical implant removed during revision. If it is discarded as medical waste, it is gone forever. We can help you coordinate with your surgeon to ensure the device is preserved and sent for forensic analysis. If you have not yet scheduled revision surgery, we can send the preservation instructions to your surgeon’s office before the operation happens.
My mother died of ovarian cancer and used talcum powder for decades — is it too late to file?
It depends on when she died and what state she lived in. Wrongful death statutes of limitations are typically shorter than personal injury statutes — often one to two years from the date of death — and they vary by state. However, if you only recently learned that her cancer may have been caused by talc, the discovery rule may apply. The personal representative of her estate is the person authorized to bring the claim. If no personal representative has been appointed, we can help with that process. Call us with the date of death and her state of residence, and we will tell you whether the window is still open.
Will joining the MDL merge my case with everyone else’s?
No. Joining an MDL does not merge your case into a class action. You keep your own individual claim with your own specific injuries, your own damages, and your own right to trial. The MDL centralizes the pretrial work — discovery, expert challenges, bellwether trials — so that shared questions are answered once rather than thousands of times. Once the pretrial work is done, your case is sent back to your home court for individual trial or settlement. You are never just a number in a pot.
How much does it cost to hire a mass tort attorney?
Nothing up front. We work on contingency — 33.33% before trial, 40% if the case goes to trial. We do not get paid unless we win your case. The consultation is free. There are no hourly bills, no retainers, no upfront costs. If we recover nothing, you owe us nothing. That is the arrangement because we believe the people injured by these products should have the same access to the courtroom as the corporations that made them.
What if I received a pre-settlement funding advance — does that affect my case?
A pre-settlement funding advance is a non-recourse cash payment against your anticipated settlement — you only repay it if you win. It does not give the funding company control over your case or your settlement decisions, and it does not affect your attorney’s ability to negotiate. However, the terms of these agreements vary widely, and some carry effective costs that consume a significant portion of your recovery. In the Depo-Provera litigation, the court has signaled interest in disclosure of funding agreements, which means your contract could become part of the litigation record. Before signing any funding agreement, have your attorney review the terms. Never sign one without understanding the repayment structure.
Can I still work with you if I live outside Texas?
Yes. We are based in Texas — Houston, Austin, and Beaumont — but mass tort litigation is nationwide. We work with local counsel in other states and appear pro hac vice (for this case) in federal courts across the country. The MDLs are federal proceedings that draw plaintiffs from every state. Where you live does not determine whether you have a case — the product you used, the injury you suffered, and the evidence you can preserve do. Call us from wherever you are.
Why Attorney911 — The Manginello Law Firm
Ralph P. Manginello is our Managing Partner — 27+ years of trial practice, licensed in Texas since November 1998, admitted to federal court in the Southern District of Texas. He was a journalist before he was a lawyer, which means he reads documents the way a reporter reads them — looking for the sentence the company did not want you to find. He has spent his career in courtrooms, including federal court, and he does not settle cases because the file is heavy. He settles them when the number is right, and he tries them when it is not. You can read more about Ralph on his attorney page.
Lupe Peña is our Associate Attorney — licensed in Texas since 2012, admitted to federal court in the Southern District of Texas, and a former insurance-defense attorney who worked inside a national defense firm. Lupe sat in the rooms where adjusters and their software decided how to deny, delay, and devalue people exactly like you. He knows the playbook because he helped write it. Now he uses that knowledge for injured clients. And Lupe is fluent in Spanish — he conducts full consultations in Spanish without an interpreter. If your family prays in Spanish, your lawyer should speak it too. You can read more about Lupe on his attorney page.
Together, we have recovered more than $50 million for our clients — a figure that includes a $5M+ brain-injury settlement, a $3.8M+ amputation settlement, a $2.5M+ truck-crash recovery, and a $2M+ maritime back-injury settlement. We currently lead the $10M+ Bermudez v. Pi Kappa Phi / University of Houston hazing lawsuit. Past results depend on the facts of each case and do not guarantee future outcomes — but they tell you what we are built to do.
We are Legal Emergency Lawyers. We answer our phone 24 hours a day, 7 days a week, with live staff — not an answering service. The consultation is free. We work on contingency — 33.33% before trial, 40% if the case goes to trial. We do not get paid unless we win your case.
Hablamos Español. Lupe conducts full consultations in Spanish, and our bilingual staff serves your family in either language.
If you or someone you love has been injured by talcum powder, Depo-Provera, or a Cartiva toe implant, the evidence that decides your case is on a clock that has already started. The preservation letter goes out the day you call. The records demands go out the day you call. The medical history starts being assembled the day you call.
Call 1-888-ATTY-911. Or contact us online. The call is free. The consultation is free. You owe nothing unless we win.
We are Attorney911 — The Manginello Law Firm, PLLC. Legal Emergency Lawyers. And we are here.